About Innate Pharma
Innate Pharma (EURONEXT:IPHA), (NASDAQ:IPHA) specializes in the development of innovative therapeutic antibodies that aim to improve the treatment of cancer. This French biotech company is focused on harnessing the immune system’s power to develop novel, first-in-class therapeutic antibodies for oncology. Innate Pharma's pipeline includes candidates in clinical and preclinical stages that target immune checkpoints and other receptors to stimulate the immune response against cancer. The company's projects are a mix of proprietary programs and collaborations with major pharmaceutical companies, aiming to address unmet medical needs in oncology. Innate Pharma's objective is to leverage its expertise in immunology and antibodies to bring new treatment options to cancer patients.
Snapshot
Operations
Products and/or services of Innate Pharma
- Monalizumab, an innovative immune checkpoint inhibitor targeting NKG2A receptors on NK and CD8 T cells, shows promise in multiple solid tumor types.
- Lacutamab, an antibody targeting KIR3DL2 for the treatment of cutaneous T-cell lymphoma and other potential indications.
- IPH6101/SAR443579, a collaboration project for natural killer cell engagers targeting various cancers, showcases their expertise in NK cell activation.
- Avdoralimab, an anti-C5aR blocker with potential in treating inflammatory diseases and certain cancers, highlights their interest in immune modulation.
- IPH5201, an antibody targeting CD39, which plays a role in immunosuppression in the tumor microenvironment, indicating their investment in cancer immunotherapy.
Innate Pharma executive team
- Mr. Jonathan E. Dickinson B.Sc., M.B.A.CEO & Director
- Mr. Yannis Morel Ph.D.Executive VP & COO
- Dr. Sonia Quaratino M.D., Ph.D.Executive VP & Chief Medical Officer
- Dr. François Romagné Ph.D.Founder
- Dr. Marc Bonneville Ph.D.Founder
- Mr. Jean Jacques Fournié Ph.D.Founder
- Mr. Alessandro Moretta M.D., Ph.D.Founder
- Mr. Frederic Lombard M.B.A.Senior VP & CFO
- Ms. Stephanie CornenVice President of Investor Relations, Communication & Commercial Strategy
- Ms. Odile BelzunceVice President of Compliance, IT & Portfolio Management